Critical Review: ASLAN Pharmaceuticals (NASDAQ:ASLN) vs. CannTrust (OTCMKTS:CNTTF)

Insider & Institutional Ownership

0.1% of CannTrust shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

CannTrust has a beta of 4.52, meaning that its share price is 352% more volatile than the S&P 500. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Profitability

This table compares CannTrust and ASLAN Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CannTrust	N/A	N/A	N/A
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

Valuation & Earnings

This table compares CannTrust and ASLAN Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CannTrust	$15.96 million	0.00	$7.39 million	$0.07	N/A
ASLAN Pharmaceuticals	$12.00 million	0.10	-$44.22 million	($21.92)	-0.03

CannTrust has higher revenue and earnings than ASLAN Pharmaceuticals. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than CannTrust, indicating that it is currently the more affordable of the two stocks.

Summary

CannTrust beats ASLAN Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

About CannTrust

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.